Methodology

PeptideTrace draws on a range of authoritative sources including regulatory agency publications, clinical trial registries, peer-reviewed scientific literature, legal databases, and government gazettes. The platform prioritises primary sources — original regulatory documents, published trial data, and official agency communications — over secondary reporting or media coverage.

Where automated data pipelines are used to monitor external sources, the ingested data is validated before it appears on the platform. The specific sources monitored continue to expand as the platform grows and new jurisdictions or data feeds are added.

Compound content follows a dual-layer approach: consumer-facing text written for accessibility, and scientific text providing technical depth. Both layers are held to the same sourcing requirements. The goal is to make complex scientific and regulatory information understandable without sacrificing accuracy or omitting important nuance.

The platform distinguishes clearly between approved pharmaceuticals with licensed therapeutic indications, investigational compounds in active clinical development, and research compounds with preclinical evidence only. This classification is visible on every compound page and determines the editorial language used throughout the platform.

For approved compounds, documented benefits may be referenced from licensed labelling. For research compounds, editorial language is deliberately restrained: “research suggests,” “animal studies indicate,” and “preclinical evidence points to” — never therapeutic claims. This is not a stylistic choice. It reflects the actual state of the evidence.

All compound content undergoes medical review prior to publication. This process ensures that clinical and scientific information is accurate, appropriately contextualised, and consistent with the current evidence base.

The platform uses a combination of automated monitoring and manual editorial review to keep data current. Automated pipelines check key external data sources on a regular cycle. Regulatory status, legal status, and clinical trial data are reviewed and updated on an ongoing basis.

When significant regulatory or legal changes occur — such as enforcement actions, status reclassifications, or clinical trial milestones — the platform aims to reflect these promptly. The regulatory tracker feed provides a chronological record of all material updates.

Accuracy is the platform’s primary obligation. If any information on PeptideTrace is found to be incorrect, outdated, or misleading, corrections are prioritised and published promptly. Factual errors are treated with urgency.

To report an error or suggest a correction: info@peptidetrace.com

PeptideTrace makes every effort to ensure the accuracy and currency of the information presented on this platform. However, the peptide regulatory landscape is complex and subject to change, and PeptideTrace cannot guarantee that all information is complete, accurate, or up to date at all times. The platform and its operators accept no liability for any decisions made or actions taken based on information published on this site. Users are advised to verify critical regulatory or legal information independently and to consult qualified professionals before making health-related decisions.